 A proposed Life Science Development Corporation, reauthorization of North Carolina’s Qualified Business Venture Tax Credit, enactment of Governor Beverly Perdue’s proposed Founders Credit, restored funding for the state’s SBIR matching grants program, and funding for the North Carolina Biotechnology Center will top NCBIO’s legislative agenda for 2010. The priorities were approved by the NCBIO Board of Directors in December.
“2010 is scheduled as the Assembly’s so-called ‘short session’,” said NCBIO President Sam Taylor, "so we will be working hard to fit a full agenda into a limited number of legislative days. However, most of these programs are already well understood by legislators, and we feel that this agenda, while challenging, is doable.”
NCBIO and the North Carolina Biotechnology Center worked with Assembly members in the State House and Senate last year to bring legislation establishing the proposed Life Science Development Corporation to the brink of passage. HB 530 (Life Science Development Act) was considered on the floor of the State House, but not acted upon, in the last days of the 2009 legislative session. The bill, which has received approval in the State Senate, would establish a state-sponsored $80 million loan fund designed to help finance new-product manufacturing and support facilities for late-stage life science start-up companies.
The State’s long-standing Qualified Business Venture Tax Credit is scheduled to sunset December 31, 2010. Legislators have typically reauthorized the credit every three years. This year’s reauthorization will probably extend the Credit through 2013. The QBV program provides tax credits against personal income tax for up to 25% of investments in qualifying small businesses. Credits for individual investments are capped at $50,000 and the State imposes a $7.5 million credit for all QBV credits in a single calendar year. The North Carolina Economic Development Board is considering recommendations that would extend the statewide cap to $10 million annually.
Governor Perdue’s proposed Founders Credit would establish an additional benefit for QBV companies by allowing investors to exclude gains from the sale of qualifying stock from income subject to personal income tax. The proposal is similar to a federal tax provision proposed in 2009 by President Obama and partially enacted as part of the American Recovery and Reinvestment Act.
NCBIO will ask legislators to make permanent appropriations for the North Carolina Board of Science and Technologies’ One North Carolina Small Business Fund. The Fund has provided matching grants of up to $100,000 to North Carolina companies that win federal SBIR and STTR awards. Funding for the One North Carolina Small Business Fund was reduced from $4.3 million to $700,000 annually in 2009 as part of stringent government cost-cutting measures adopted by the Assembly. NCBIO hopes to persuade legislators that recovering revenues should be first deployed to stimulate new company and job creation through the program.
NCBIO will also support restoration and expansion of funding for the North Carolina Biotechnology Center in 2010. Legislators reduced the Center’s budget by 4% in FY 2009-10 and 6% in FY2010-11. The cuts were comparable to similar reductions imposed on most state agencies as legislators dealt with an anticipated $4 billion revenue shortfall. Governor Beverly Perdue has since imposed an additional 5% cut in government spending – including funding for the Center – as a precautionary measure addressing continued declines in state revenue.
“As always, there are significant projects that we will not be able to address the session,” said Taylor. “However, we are hopeful that the 2011 legislative session will provide us opportunities to bring forward some new ideas about life science infrastructure and economic development that we can only hope to fully explain to legislators during a long session.”
For a fuller discussion of matters of potential legislative interest in 2010 and 2011, click to view the Organization’s memorandum to the North Carolina Board of Economic Development concerning policy issues facing North Carolina’s innovation economy.
 State Treasurer Janet Cowell has established a new innovation-oriented investment as a subset of the State’s Private Equity Investment Program (PEIP). According to the Treasurer's Office, the primary purpose of the Innovation Fund is “to accomplish competitive risk-adjusted rate of return consistent with the performance objective of PEIP,” and to support the well-being of the State of North Carolina.
The Treasurer’s office released a request for proposals from potential fund managers in late November. Responses were due in December. NCBIO Update will report more information as it becomes available.
Governor Beverly Perdue today has established a new North Carolina Innovation Council to foster strategic investments and policies in the growing knowledge and innovation economy. Perdue made the announcement after touring a lab in the Wake Forest Institute for Regenerative Medicine in Winston-Salem.
“To continue growing jobs in North Carolina we must make sure this state is poised to compete globally in the 21st century,” said Perdue. “Innovation is North Carolina’s launch pad to success in the global economy, and it’s a primary way for us to maintain and sharpen our competitive edge.”
The new Council will advise the Governor on a variety of innovation-related matters, including
- Coordinating public and private investments and policies to promote innovation;
- Moving innovative ideas from the lab to the marketplace more efficiently; and
- Strengthening collaboration among business, academia, state and local government.
The Council’s membership will draw on a broad spectrum of expertise in entrepreneurship, science, academia and government. It will be co-chaired by Steve Nelson, managing partner of the Wakefield Group, and Al Delia, senior advisor to the Governor.
“North Carolina has a rich history of innovation with its high-impact businesses, championed by world-class leaders and entrepreneurs. Yet the opportunity in front of us is to build on this strength. I very much look forward to working with this distinguished group to encourage investment, bring jobs to North Carolina, and grow our economy,” said co-chair Steve Nelson.
Other members of the Innovation Council include Norris Tolson, President of the North Carolina Biotechnology Center; Joan Seifert Rose, President of CED; Dr. Richard Stack, Chairman of Synecor; Karen LeVert, CEO of Southeast TechInventures; and Garheng Kong, Partner, Intersouth Partners.
John Wagner, Plant Manager at Merck’s Maurice Hilleman Center for Vaccine Manufacturing in Durham, has been elected Chairman of the NCBIO Biotech Manufacturers Forum (BMF). Mr. Wagner succeeds Mark Paige of Novozymes North America.
Mr. Wagner thanked the members for their confidence and reiterated the importance of the Forum’s continuing support for the state’s NCBioImpact biomanufacturing education and training program. NCBioImpact, which includes the Golden LEAF Biomanufacturing Training and Education Center (BTEC) at North Carolina State University, the Biomanufacturing Research Institute and Technology Enterprise (BRITE) at North Carolina Central University, and the North Carolina Community College System’s statewide BioNetwork program, was established in 2006 based on the biomanufacturing industry’s growing need for qualified workers. Mr. Wagner told BMF members that the Forum needs to continue providing technical support and guidance to the NCBioNetwork partners.
Sam Taylor, President of NCBIO presented a resolution from NCBIO and BMF honoring Mr. Paige. The resolution recognizes Mr. Paige’s work on behalf of the state’s biomanufacturing industry and his support of worker training programs since the beginning of the NCBioImpact program.
Also at the December BMF meeting, members heard from a panel on “Keys to Developing an Effective Flexible or Cross Trained Workforce.” Panelists were: Neil Chinault, Director of Technical Service, Pfizer/Wyeth; Mike Hess, Senior Manager, Production, Novozymes; Steven Howell, Operations Excellence Manufacturing Leader, W.L. Gore; and Andy Stober, Director of Manufacturing Sciences, Biogen Idec. Each of the panelists outlined steps his company has taken to cross train workers and the impact those efforts have had on improving efficiency and strengthening the skills of employees.
For more information about BMF, contact Bruce Kaylos, NCBIO Program Manager for the Forum.
The North Carolina Biotechnology Center has hired Gwyn Riddick to a newly created position: Vice President, Ag/Bio Initiative. Riddick, who previously served as director of the Center’s Piedmont Triad office, will help launch an initiative to grow the state's agricultural economy to $100 billion during the next 10 years.
"We have a deep history and tremendous assets in agriculture in North Carolina," said Norris Tolson, President and CEO of the Biotechnology Center. "We identified this opportunity to combine that heritage and our strength in new technology to create wealth across the state of North Carolina, and to improve the quality of life for people around the world."
Riddick brings more than 40 years of experience to his new post - in education, consumer products, diagnostics, blood products and pharmaceuticals including human and animal vaccines. "We have hardly begun to tap the natural, renewable resources of agriculture that will benefit mankind," Riddick said. "Integrating biotechnology and agriculture is an integral platform for our future, and I am eager to get started."
More than 200 people are now employed on the North Carolina Research Campus in Kannapolis. Eight universities are co-located and have research activities under way at the facility, and partnerships have been developed with a number of other academic institutions, both in and out of state, according to Dr. Michael Luther, President of the David H. Murdock Research Institute (DHMRI), the on campus, world-class laboratory facility with state-of-the-art instrumentation and research.
In addition to the universities, Rowan Cabarrus Community College is nearing completion of a new facility at the Research Campus that will offer an AAS degree in biotechnology research and development.
“We made a lot of progress in the past three years -- from a site with rubble on the ground to a fully operational campus,” stated Dr. Luther. “In 2009, we were able to get all platforms up and running at DHMRI to a fully functional campus where research and development activities are now underway. David Murdock’s vision is now being implemented. We have brought together leading researchers in a multi-disciplinary, multi-university, public and private effort that focuses on the intersection of human health, agriculture and nutrition to discover and develop new ways to improve and impact human health. I believe 2010 could be a tipping point for the Campus as the economy improves.”
Eight companies are currently located on the site, and Campus representatives are in active discussions with a number of potential prospects. In addition, DHMRI and the universities are working and collaborating closely with scientists around the world both in academia and industry to make new discoveries and further product development in these fields.
Among the research programs now active at the Campus the “M.U.R.D.O.C.K” Study, an epidemiological project partnership between Duke University, local healthcare providers, DHMRI, and the Kannapolis and Cabarrus communities. The Study is focused on redefining human disease using traditional and cutting edge clinical technologies and methods.
At the Plants for Human Health Institute (PHHI), North Carolina State University scientists are focused at identifying and characterizing bioactive compounds found in foods, such as vegetables and berries that confer human health benefits. Also at PHHI, researchers at the Appalachian State University Human Performance Laboratory are looking at the intersection of nutrition and exercise immunology. In a parallel effort at the Campus’ Nutrition Research Institute, UNC-CH scientists are developing innovative approaches to understanding the role of diet and activity in normal brain development, cancer prevention, and the prevention and treatment of obesity.
“We are continuing our efforts to partner and work with universities as well as start-up and established companies to drive early research to proof-of-concept, so that we can rapidly develop and commercialize opportunities in the areas of health, nutrition and agriculture,” stated Dr. Luther. “In 2010, we’ll be focusing on expanding our efforts to both establish and expand our key capabilities and expand our partnerships and interactions with universities and companies. It is important for us to get the message out regarding who and what the North Carolina Research Campus is. In 2010, we will be more aggressive in branding the North Carolina Research Campus and in bringing the right partners and partnerships to the campus.”
The impact of health care reform is just one of the topics that will be discussed at Biotech 2010, February 22-23 at the Raleigh Convention Center. The annual event is sponsored by CED and co-hosted by NCBIO and the North Carolina Biotechnology Center. Featured panelists include: Steve Stefano, former Senior Vice President, GlaxoSmithKline (Moderator); Lanier M. Cansler, Secretary, North Carolina Department of Health and Human Services; Kevin Schulman, Professor of Medicine, Duke University; Anthony Y. Sun, Partner, Aisling Capital; J. Bradley Wilson, President and Chief Operating Officer, Blue Cross and Blue Shield of North Carolina.
Talecris Biotherapeutics CEO, Larry Stern will be part of a panel on Financing in the Current Environment. Another speaker is the former CEO of CV Therapeutics, Inc. (acquired by Gilead Sciences), Dr. Louis Lange, PhD, who is currently a general partner with Asset Management.
Other topics include: Leadership in Challenging Times; Opportunities in Personalized Medicine; and Opportunities and Challenges in Global Health.
More than 1000 entrepreneurs, investors, executives and service partners are expected for the event. Take advantage of early registration rates and save $100 before January 20. Click to register.
Don’t miss your chance to be a part of the North Carolina life science community at BIO 2010 in Chicago. The North Carolina Biotechnology Center, in partnership with the Department of Commerce and NCBIO, is planning an impressive showcase of the state's life-science community at the annual BIO International convention in Chicago May 3-6, 2010.
You can exhibit at BIO for as little as $1,000. Joining the North Carolina Pavilion is more cost effective than staging your own exhibit booth, and it offers many benefits. The North Carolina Pavilion has a prominent location on the exhibit hall floor, and its 2,000 sq-ft design includes video screens and a conference room. It also provides networking opportunities with the hundreds of company leaders and state dignitaries that stop by each year, as well as at the exclusive Friends of North Carolina Reception in the Willis Tower.
 The Fuqua School of Business, in partnership with the new Duke Center for Health Informatics, has introduced the Master’s of Management in Clinical Informatics (MM CI). Enrollment for this new program begins August 2010; the first class will graduate in May 2011.
The one-year Management in Clinical Informatics program is the only interdisciplinary management program of its kind in the United States and leverages Duke’s world-renowned track record in medicine, business and health informatics. Through access to the finest faculty and resources across health care, IT and management education, students will acquire the knowledge and skills to merge technology and patient care and help improve human health.
Please have your organization’s media/marketing coordinator send news about your company to Brenda Summers - bsummers@ncbioscience.org
Liquidia Technologies announced that it will receive approximately $3 million in funding from the U.S. Commerce Department’s National Institute of Standards and Technology (NIST) to further develop and scale‐up the company’s PRINT manufacturing process. As part of its Technology Innovation Program (TIP), NIST announced it will fund new cost‐sharing projects to support innovative technologies that address critical national needs.
“We are very excited to have been selected by NIST as one of the 20 projects to receive funding through the TIP program,” said Tom Templeman, Senior Vice President, Integrated Supply Chain at Liquidia. “This investment will support our continued development of PRINT manufacturing, which will allow us to develop clinically relevant quantities of particles for innovative vaccines and therapeutics.”
Pappas Ventures announced that Sean McCarthy has been named Transactional Partner. The firm also promoted Scott Weiner to Senior Principal. McCarthy joined Pappas in 2006 as Principal, after gaining 10 years of experience in business development, program management and research management in the biotech industry. Scott Weiner joined Pappas Ventures in 2006 as a Senior Associate, and prior to that was an investment manager and research analyst for Silverback Asset Management's life sciences fund.
“We are pleased to recognize the significant contributions that Sean and Scott have made to the development and success of our firm,” said Eric Linsley, Pappas Ventures’ managing partner. “They both know how to build value for our portfolio companies – and our investors.”
Pappas Ventures also announced that industry veteran Michael Grey has been named a venture partner. Grey’s role as venture partner at Pappas Ventures represents an expansion of his long-standing relationship with the firm, which includes his tenure over the past six years as a member of Pappas Ventures’ Scientific Advisory Board.
Ten lawyers from Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. have been named to the 2010 Legal Elite list by Business North Carolina magazine. Those honored include: Christopher Capel - Business Law, Rose Kenyon – Employment, Kim Korando – Employment, Pete Marino – Construction, Merrill Mason – Corporate, Steve Mason - Real Estate (Hall of Fame), Gerald Roach - Business Law (Hall of Fame), Walter Rogers - Tax, Estate Planning, Mike Saber - Intellectual Property and, Sammy Thompson – Litigation.
Martin Lancaster, a lawyer with Smith Anderson, has been elected Chairman of the Defense/Aerospace Aviation Advisory Committee for North Carolina’s Eastern Region (NCER). As Chairman, he will lead the committee’s efforts to build the defense/aerospace industry in North Carolina. Lancaster’s work with Smith Anderson focuses on Corporate Relocations and Expansions and Life Sciences. He joined the firm after retiring as president of the North Carolina Community College System, a post he held since 1997.
Syngenta Biotechnology, Inc., (SBI), celebrated its 25th anniversary in the Research Triangle Park as a world-class facility for crop genetics research and discovery. SBI opened its doors in 1984 and since then has expanded into nearly 200,000 square feet of laboratories, offices and greenhouse space. The facility serves as the key North American location for plant gene technology research for Syngenta, and employs over 400 staff.
“SBI remains a leader in developing new products that help farmers meet the demands of a growing global population,” said SBI president and global head of biotechnology R&D Michiel van Lookeren Campagne. “SBI is home to some of the key genetic research milestones in agriculture and continues to combine technology with talent and expertise to create innovative new tools and integrated solutions for growers.”
Targacept, Inc. and AstraZeneca have announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD). TC-5214, which recently completed a Phase 2b clinical trial, is a nicotinic channel blocker that is thought to treat depression by modulating the activity of various neuronal nicotinic receptor (NNR) subtypes. J. Donald deBethizy, Ph.D., President and Chief Executive Officer of Targacept, said: “We are delighted to have selected AstraZeneca to work with us to meet our goal of advancing TC-5214 into late-stage development and bringing a new mechanistic approach for the treatment of depression to the millions of patients who do not respond well to first-line antidepressant therapy and need relief. Targacept and AstraZeneca have an established track record of successful collaboration and today’s agreement demonstrates our shared dedication to excellence in the field of neuroscience.”
Targacept, has also announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia. TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, or NNR, and was discovered by Targacept scientists using Targacept’s proprietary drug discovery platform known as PentadTM. “We believe that currently available treatment options do not adequately address the dramatic impact schizophrenia has on cognition for millions of patients. Medications capable of improving attention and reasoning in these patients are needed to improve their quality of life,” said Dr. deBethizy,. “The scientific literature is replete with evidence of the key role that the alpha7 NNR plays both in cognitive function and in the psychoses characteristic of schizophrenia. TC-5619 is highly selective for the alpha7 NNR and has to date shown little or no interaction with the 5-HT3 receptor, which is known to be associated with significant limiting side effects that have served as an obstacle to the successful development of other alpha7 NNR modulators.”
TCG, LLC will run workshops on "How to Enter the US Market" February 3 & 5 in Cambridge and Frankfurt. European colleagues can get details and advice on business development strategy and implementation at the new company website www.tcgmedtech.com.
Tranzyme Pharma has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb. The collaboration will deploy Tranzyme’s proprietary drug discovery technology, Macrocyclic Template Chemistry (MATCH™), to identify and develop new drug candidates for multiple targets in diverse therapeutic areas.
Bristol-Myers Squibb will provide an upfront payment of $10 million and an additional $3 to $6 million in research funding to Tranzyme for an initial two-year term. Tranzyme will receive further funding if the agreement is extended beyond the initial term. In addition, Tranzyme is eligible to receive development and regulatory milestones and tiered royalties for each product resulting from the collaboration. Total milestone payments under the agreement, excluding royalties, could reach up to approximately $80 million for each target program.
“We are excited to be joining forces with Bristol-Myers Squibb; we believe they will be an ideal partner to exploit the versatility of our proprietary chemistry,” said Vipin K. Garg, PhD, Tranzyme’s President and CEO. “In addition to Tranzyme’s current focus on gastrointestinal and metabolic disease targets, MATCH™ has broad applicability in the treatment of other diseases that involve hormones, peptides, ion channels or protein-protein interaction pathways.”
 BIO Applauds Senate Health Care Bill
BIO President and CEO Jim Greenwood has praised health reform legislation passed by the U.S. Senate. “The health care reform bill passed by the Senate includes many provisions which serve as early Christmas presents for patients living with debilitating diseases such as cancer, Multiple Sclerosis, HIV/AIDS and a host of rare diseases,” said Greenwood. “These provisions are a triumph for sick patients and their families. They are important steps toward realizing the critical broad goals of health care reform, namely reducing costs, expanding access and promoting continued medical breakthroughs that lead to new, improved and more efficient treatments for patients.”
“This bill establishes, for the first time ever, a pathway to allow for U.S. Food and Drug Administration approval of biosimilars, sometimes inaccurately referred to as ‘biogenerics’. Through this provision, authored by Senators Kay Hagan (D-NC), Mike Enzi (R-WY), Orrin Hatch (R-UT) and Barbara Mikulski (D-MD), patients with devastating diseases will have increased access to safe and effective life-saving advanced therapies and can take comfort in the knowledge that this bill will accelerate the biotechnology sector’s drive toward discovering new treatments, therapies and cures for diseases that have plagued us for years,” Greenwood said. “We look forward to working with these senators to ensure a biosimilars pathway is created, and that the House provisions pertaining to patent resolution are included in the final bill.”
Greenwood added, “The Senate bill also provides relief to investment-starved small biotechnology research companies by creating a therapeutic discovery project tax credit. This proposal, authored and championed by Senator Bob Menendez (D-NJ), would support small and emerging biotechnology companies by providing a tax credit to help offset a portion of resources spent on therapeutic development activities, including hiring scientists and conducting clinical studies. These credits would help sustain projects that likely will lead to new therapies to treat areas of unmet medical need, address chronic or acute diseases, reduce long-term health care costs, or significantly advance President Obama’s challenge to cure cancer in our lifetime. This provision will create and save thousands of U.S. jobs. It is our strong hope that any final bill contains this pro-innovation, pro-job therapeutic discovery tax credit provision.”
“Similarly, Senator Arlen Specter’s (D-PA) Cures Acceleration Network (CAN), established under the Senate bill, will help speed the development of next generation medicines, treatments and cures by providing federal grants to promising projects in the public, private, academic and research communities. This provision also will help expedite FDA review of highly innovative safe and effective treatments for patients,” Greenwood stated.
BIO Commends Legislation That Will Help Small Biotech Companies
BIO President and CEO Jim Greenwood commended the U.S. House of Representatives for including provisions intended to ease small business regulatory burdens as part of the Wall Street Reform and Consumer Protection Act of 2009 (H.R. 4173), which passed in December.
Two provisions in the bill would ease regulatory burdens for small public biotechnology companies. A provision authored by Reps. Scott Garrett (R-NJ) and John Adler (D-NJ) would permanently exempt companies with market capitalizations of $75 million or less from Section 404(b) of the Sarbanes-Oxley Act of 2002 (SOX). An amendment offered on the House floor to remove this language was rejected by a broad, bipartisan vote, with 101 Democrats and 170 Republicans voting in support of the Garrett-Adler language.
Additionally, Rep. Michael Capuano (D-MA) authored a provision that would direct the Securities and Exchange Commission (SEC) to perform a study evaluating the costs and benefits of compliance with SOX Section 404(b) for companies that have public floats of less than $700 million and revenues less than $250 million.
“These bipartisan provisions would provide much needed relief for small public biotechs during the current economic conditions. Currently, 41% of active publicly traded biotech companies fall under $75 million in market cap,” stated Mr. Greenwood. “We urge the Senate Committee on Banking, Housing and Urban Affairs to include similar provisions in its financial services reform bill.”
Federal Grants and Loans Will Help Biofuels Production
The Biotechnology Industry Organization has applauded the announcement of over $600 million in grants and loan guarantees to help build 19 new biorefinery projects to produce advanced biofuels and bio-based chemicals from renewable feedstocks. The funding represents the largest single federal investment in advanced biorefineries to date.
"This unprecedented investment by DOE and USDA shows how important advanced biofuels and biobased chemicals are to the economic and energy security of the country," said Jim Greenwood, President and CEO of BIO. "These are precisely the kind of projects the Recovery Act should be funding - creating jobs while helping the country move to a more sustainable industrial future."
A recent report by Bio Economic Research Associates (bio-era™), U.S. Economic Impact of Advanced Biofuels Production: Perspectives to 2030, found that advanced biorefineries could create 29,000 new jobs and $5.5 billion in economic growth over the next three years - and over 800,000 new jobs throughout the economy by 2022. The awards will fund pioneering production of breakthrough cellulosic and algae-based fuels and renewable alternatives to fossil-based chemicals, such as Succinic acid.
US International Trade Commission Studying Biotechnology Export Barriers
The U.S. International Trade Commission (USITC) has launched the second of three studies that will examine the extent and composition of U.S. exports by small and medium-sized enterprises (SMEs) and factors that may disproportionately impede U.S. SME exports. The study has targeted biotechnology as an area of particular interest.
The second report, Small and Medium-Sized Enterprises: U.S. and EU Export Activities, and Barriers and Opportunities Experienced By U.S. Firms, will analyze the performance of U.S. SME firms in exporting compared to SMEs exporting in other leading economies. It will also identify barriers to exporting noted by U.S. SMEs and strategies used to overcome special constraints and reduce trade costs, as well as the benefits to SMEs from increased export opportunities, including free trade agreements and other trading arrangements. The USITC will deliver the report to the USTR by July 6, 2010.
The USITC will hold a hearing in connection with this investigation in Washington, DC, on February 9, 2010. Requests to appear at the Washington hearing should be filed no later than 5:15 p.m. on January 26, 2010, with the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. For further information, call 202-205-2000. Written comments may be submitted before March 26, 2009.
February 10, 2010
NUTech 2010 Nagoya University Technology Showcase, Sheraton Imperial Hotel & Convention Center, RTP. Discover new opportunities in uncommercialized technologies from a leading research university in Japan. More than 20 life science, biotech and engineering technologies will be showcased from Nagoya University, Japan. This premier Showcase event in RTP will feature Nagoya University’s cutting edge technologies in life and science engineering sectors. There is no charge for registration. Click for more information.
February 22-23, 2010.
CED's Biotech Conference: Fusing Science, Technology and Industry Leadership, Raleigh Convention Center, Raleigh. CED's annual Biotech Conference unites the Southeast life science community to celebrate one of the biotech industry's most dynamic regions. This two-day conference includes world-class speakers, a variety of panels on industry topics and trends, and networking opportunities with life science leaders. Join industry executives, including the region's most innovative biotech entrepreneurs, major pharmaceutical companies, research leaders, policy makers and nationally prominent investors at the Southeast's premier life science event - CED's Biotech 2010 Conference. For more information.
April 6-8, 2010.
Translational Regenerative Medicine Forum, Benton Convention Center, Winston-Salem, NC. This event advances the field of regenerative medicine and healthcare innovation through the sharing of scientific discoveries, best practices and business models. The meeting will also feature a venture forum showcasing international regenerative medicine companies and investors from corporate venture, venture philanthropy, private equity and venture capital firms. For more information go here.
April 20-22, 2010.
CED's Venture Conference: Where Great Minds Meet Smart Money, Pinehurst Resort, Pinehurst, NC. For the past 25 years, CED’s Venture conference has created business opportunities for hundreds of entrepreneurs and investors across North Carolina and the Southeast. As the nation’s longest running financing event, CED’s Venture showcases the region’s most promising companies to an audience of top tier investors and entrepreneurial leaders. For more information, click here.
| 
NCBIO This Month
Bio Links
